MX2021008017A - Formulaciones de colagenasa y metodos de produccion de las mismas. - Google Patents
Formulaciones de colagenasa y metodos de produccion de las mismas.Info
- Publication number
- MX2021008017A MX2021008017A MX2021008017A MX2021008017A MX2021008017A MX 2021008017 A MX2021008017 A MX 2021008017A MX 2021008017 A MX2021008017 A MX 2021008017A MX 2021008017 A MX2021008017 A MX 2021008017A MX 2021008017 A MX2021008017 A MX 2021008017A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- collagenase
- formulations
- production
- collagenase formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788916P | 2019-01-06 | 2019-01-06 | |
| PCT/US2020/012202 WO2020142701A1 (en) | 2019-01-06 | 2020-01-03 | Collagenase formulations and methods of producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008017A true MX2021008017A (es) | 2021-08-05 |
Family
ID=69845512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008017A MX2021008017A (es) | 2019-01-06 | 2020-01-03 | Formulaciones de colagenasa y metodos de produccion de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20220305094A1 (https=) |
| EP (1) | EP3906014A1 (https=) |
| JP (2) | JP7565280B2 (https=) |
| KR (1) | KR20210113271A (https=) |
| CN (1) | CN113382714A (https=) |
| AU (2) | AU2020204922B2 (https=) |
| BR (1) | BR112021012675A2 (https=) |
| IL (2) | IL321891A (https=) |
| MX (1) | MX2021008017A (https=) |
| WO (1) | WO2020142701A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113025599B (zh) * | 2021-04-02 | 2023-09-12 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌i型胶原酶及其制备方法和应用 |
| CN112941058B (zh) * | 2021-04-02 | 2023-12-05 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 |
| CN114264633B (zh) * | 2022-02-10 | 2022-09-06 | 上海蓝长科技集团有限公司 | 一种福尔马肼聚合物冻干粉及制备方法 |
| AU2023232693A1 (en) * | 2022-03-08 | 2024-09-19 | Connext Co.,Ltd. | Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase |
| CN119656117B (zh) * | 2024-12-18 | 2025-08-29 | 远大生命科学(鞍山)有限公司 | 一种药物组合物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2921180B1 (en) * | 1999-02-22 | 2019-08-14 | University of Connecticut | Albumin-free factor VIII formulations |
| US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| CN101312744A (zh) | 2005-11-22 | 2008-11-26 | 惠氏公司 | 免疫球蛋白融合蛋白制剂 |
| US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| ES2388219T3 (es) * | 2008-06-02 | 2012-10-10 | F. Hoffmann-La Roche Ag | Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum |
| WO2012125948A1 (en) | 2011-03-16 | 2012-09-20 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
| JP2014530873A (ja) * | 2011-10-21 | 2014-11-20 | オーキシリウム インターナショナル ホールディングス，インコーポレイテッド | Ｅｆｐの治療または低減方法 |
| PT2802652T (pt) | 2012-01-12 | 2019-09-10 | Endo Global Ventures | Enzimas de clostridium histolyticum |
| EP3834840B8 (en) | 2013-03-15 | 2025-09-17 | Endo Biologics Limited | Treatment method and product for uterine fibroids using purified collagenase |
| US10137179B2 (en) * | 2016-05-18 | 2018-11-27 | Hyalo Technologies, LLC | Composition and method of preparation of protease microparticulate slow release preparation |
| CA3039655A1 (en) * | 2016-10-07 | 2018-04-12 | Regeneron Pharmaceuticals, Inc. | Room temperature stable lyophilized protein |
| EP4591945A3 (en) * | 2017-03-01 | 2026-04-15 | Endo Operations Limited | Apparatus and method for assessing and treating cellulite |
-
2020
- 2020-01-03 US US17/419,899 patent/US20220305094A1/en not_active Abandoned
- 2020-01-03 AU AU2020204922A patent/AU2020204922B2/en active Active
- 2020-01-03 WO PCT/US2020/012202 patent/WO2020142701A1/en not_active Ceased
- 2020-01-03 IL IL321891A patent/IL321891A/en unknown
- 2020-01-03 BR BR112021012675-9A patent/BR112021012675A2/pt active Search and Examination
- 2020-01-03 MX MX2021008017A patent/MX2021008017A/es unknown
- 2020-01-03 KR KR1020217024557A patent/KR20210113271A/ko not_active Ceased
- 2020-01-03 CN CN202080010875.3A patent/CN113382714A/zh active Pending
- 2020-01-03 JP JP2021539410A patent/JP7565280B2/ja active Active
- 2020-01-03 IL IL284270A patent/IL284270B2/en unknown
- 2020-01-03 EP EP20712071.8A patent/EP3906014A1/en active Pending
-
2023
- 2023-09-29 US US18/478,368 patent/US12303557B2/en active Active
-
2024
- 2024-09-30 JP JP2024169863A patent/JP2025016453A/ja active Pending
-
2025
- 2025-04-22 US US19/185,838 patent/US20250249080A1/en active Pending
- 2025-06-30 AU AU2025204915A patent/AU2025204915A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022516569A (ja) | 2022-02-28 |
| IL321891A (en) | 2025-09-01 |
| AU2025204915A1 (en) | 2025-07-24 |
| AU2020204922B2 (en) | 2025-04-24 |
| IL284270A (en) | 2021-08-31 |
| JP7565280B2 (ja) | 2024-10-10 |
| CN113382714A (zh) | 2021-09-10 |
| JP2025016453A (ja) | 2025-02-04 |
| BR112021012675A2 (pt) | 2021-09-28 |
| CA3125007A1 (en) | 2020-07-09 |
| US20250249080A1 (en) | 2025-08-07 |
| WO2020142701A1 (en) | 2020-07-09 |
| US20240041993A1 (en) | 2024-02-08 |
| US20220305094A1 (en) | 2022-09-29 |
| IL284270B1 (en) | 2025-08-01 |
| US12303557B2 (en) | 2025-05-20 |
| KR20210113271A (ko) | 2021-09-15 |
| AU2020204922A1 (en) | 2021-07-01 |
| EP3906014A1 (en) | 2021-11-10 |
| IL284270B2 (en) | 2025-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008017A (es) | Formulaciones de colagenasa y metodos de produccion de las mismas. | |
| CO2019012893A2 (es) | Composiciones farmacéuticas de atropina | |
| MX2020012765A (es) | Métodos y compuestos de ácido nucleico modificado con lípidos. | |
| UY37563A (es) | Aislados de bacillus y usos de los mismos | |
| CO2018005361A2 (es) | Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración | |
| CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
| AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
| CL2020002698A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| AR120534A1 (es) | Aislados paenibacillus y sus usos | |
| CO2019009258A2 (es) | Administración rápida y controlada de composiciones con efectos séquito restaurados | |
| DOP2018000257A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| UY37564A (es) | Aislados de lysinibacillus y usos de los mismos | |
| MX2019015877A (es) | Método para mejorar el rendimiento o la calidad de los cultivos. | |
| MX2018005925A (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| CO6470858A2 (es) | Composición tensioactiva reconstituida mejorada que contiene análogos de la proteína tensioactiva b (sp-b) y de la proteína tensioactiva c (sp-c) | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| MX2016006488A (es) | Formulacion liofilizada de conjugado de anticuerpo-farmaco. | |
| MX2012011504A (es) | Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa). | |
| MX2021000328A (es) | Enzimas de variantes de galactosa oxidasa modificadas geneticamente. | |
| MX385109B (es) | Formulaciones de anticuerpos. | |
| EA202190331A1 (ru) | Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки | |
| BR112013001753A2 (pt) | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. | |
| BR112017005231A2 (pt) | formulações eutéticas de cloridrato de ciclobenzaprina | |
| MX2025004075A (es) | Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos | |
| UY36920A (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral |